<DOC>
	<DOCNO>NCT02450253</DOCNO>
	<brief_summary>Could Tadalafil improve blood flow deep brain tissue potentially improve cognitive function patient cerebral small vessel disease</brief_summary>
	<brief_title>Perfusion Arterial Spin Labelling Following Single Dose Tadalafil Small Vessel Disease ( PASTIS ) Trial</brief_title>
	<detailed_description>Cerebral small vessel disease ( SVD ) primary cause vascular cognitive impairment ( VCI ) , severe form manifest vascular dementia ( VaD ) . SVD fibrous thicken small penetrate artery deep brain nucleus ( basal ganglion , thalamus ) subcortical white matter.Clinical study suggest pure VCI/VaD contribute approximately 8-15 % dementia old people Reduced CBF well establish VCI . Improved blood flow vasculature deep white grey matter therefore attractive mechanism slow pathology VCI valuable biomarker initial proof concept study . To increase likelihood success full scale clinical trial tadalafil VCI , study test effect single dose tadalafil cerebral blood flow subject SVD use ASL-MRI . A strict definition SVD use combine clinical MRI criterion . Phosphodiesterase-5 ( PDE5 ) specifically degrade cGMP within cell ; limit activation protein kinase G. Guanylyl cyclase enzymes generate cGMP , downstream NOS-nitric oxide signal . PDE5 inhibitor SVD . PDE5 blockade plausible strategy improve local cerebral blood flow ( CBF ) , deep brain area afflict SVD . By augment NO-cGMP-PKG pathway , PDE5i drug expect vaso-relaxant small artery myocytes . In patient pulmonary hypertension sildenafil improve cerebral vascular reactivity response hypercapnic challenge , indicative improvement neurovascular coupling . Similar increase reactivity record 60 min administration sildenafil ED patient . By contrast , healthy volunteer show change MCA blood flow follow sildenafil , similar healthy rodent , vasodilation occur high concentration drug . Overall appear PDE5i may little effect `` healthy '' cerebral artery rodent human . Prior human study single dose study PDE5i healthy human , use sildenafil general estimate CBF Middle Cerebral Artery ( MCA ) blood flow use Trans Cranial Doppler ( TCD ) . MCA blood flow may reflect local blood flow microvasculature deep white deep grey matter . One study examine effect single dose sildenafil CBF use SPECT patient vascular risk factor without history stroke . Non-stroke patient exhibit overall increase CBF . However , distinction make study large vessel lacunar stroke . In summary , pre-clinical study support CBF-enhancing action PDE5i cerebrovascular disease , human study date limit sildenafil specifically address effect CBF people SVD . Tadalafil ( Cialis® ) widely-used oral agent sexual dysfunction . As inhibitor enzyme PDE5 , tadalafil well-established pharmacological profile small vessel vasodilator . Side-effect profile pharmacokinetics well know drug well-tolerated target population , range oral dos regimen . The choice tadalafil PDE5 inhibitor ( sildenafil , Viagra® ) base potency , selectivity PDE5 , plasma half-life document brain penetration . Phosphodiesterase-5 ( PDE5 ) specifically degrade cGMP within cell ; limit activation protein kinase G. Guanylyl cyclase enzymes generate cGMP , downstream NOS-nitric oxide signalling . The PDE5 inhibitor sildenafil ( Viagra® ; discover Pfizer , Sandwich UK ) raise profile PDE5 therapeutic target . Tadalafil ( Cialis® ; licence holder : Eli Lilly ) widely prescribe `` require '' basis ED men . It also license regular daily use dose 5 mg benign prostatic hyperplasia 40 mg pulmonary hypertension . Tadalafil well tolerate side effect profile well-established</detailed_description>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Dementia , Vascular</mesh_term>
	<mesh_term>Tadalafil</mesh_term>
	<criteria>1 . Radiological evidence cerebral small vessel disease define : MRI evidence lacunar infarct ( ) ( ≤ 1.5 cm maximum diameter ) and/or confluent deep white matter leukoaraiosis ( ≥ grade 2 Fazekas scale ) 2 . Clinical evidence cerebral small vessel disease : 1. lacunar stroke syndrome symptom last &gt; 24 hour , occur least 6 month previously ; OR : 2. transient ischaemic attack last &lt; 24 hour limb weakness , hemisensory loss dysarthria least 6 month previously AND MRI DWI perform acutely show lacunar infarction , OR MRI perform within 10 day TIA , lacunar infarction anatomically appropriate position demonstrate subsequent MRI 3 . Age ≥ 55 year . 4 . Imaging carotid artery Doppler ultrasound , CT angiography MR angiography previous 12 month , demonstrate &lt; 70 % stenosis internal carotid artery 1 . Known diagnosis dementia 2 . Cortical infarction ( &gt; 1.5 cm maximum diameter ) 3 . Systolic BP &lt; 90 and/or diastolic BP &lt; 50 4 . Creatinine Clearance &lt; 50ml/min 5 . Severe hepatic impairment 6 . History Lactose intolerance 7 . Concomitant use PDE5 inhibitor e.g . sildenafil , tadalafil , vardenafil . 8 . Concomitant use alphablockers e.g . alfuzosin , doxazosin , indoramin , prazosin , tamsulosin , terazosin increase risk postural hypotension . 9 . Participants receive nicorandil nitrate e.g . isosorbide mononitrate , isosorbide dinitrate , glyceryl trinitrate 10. weight &gt; 130kg 11 Uncontrolled cardiac failure 12 . Persistent paroxysmal atrial fibrillation 13 . History gastric ulceration 14 . History 'sick sinus syndrome ' supraventricular cardiac conduction condition sinoatrial atrioventricular block 15 . Uncontrolled COPD 16 . Stroke TIA within last 6 month 17 . MRI tolerate contraindicate : MRI exclusion criterion Participant cardiac pacemaker ; recent surgery ; vascular clip ; metal implant joint replacement ; metal fragment eye ; ever work lathe ; shrapnel war injury ; possibility pregnancy 18 . Known monogenic cause stroke e.g.. CADASIL 19 Unable provide inform consent 20. enrol another CTIMP study</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Vascular cognitive impairment</keyword>
</DOC>